Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
NCT02052141
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Hereditary Angioedema (HAE)
Interventions
BIOLOGICAL:
CINRYZE 500
BIOLOGICAL:
CINRYZE 1000
Sponsor
Shire